Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Oral Proteins and Peptides Market Analysis and Forecast 2024-2031
Chapters cover methodology, executive summary, market variables, segmentation by disease, molecule, biological target, mechanism, and region, and competitive landscape.
Epilepsy Clinical Trials 2024: EMA, PDMA, FDA Approvals
DelveInsight's 'Epilepsy Pipeline Insight, 2024' report details 75+ companies developing 90+ therapies, including RLS103, CT-010, EQU 001, and others, with insights on mechanism of action, route of administration, and clinical trials. Key companies include Novartis, Pfizer, Sanofi, and Takeda, among others.
Related Clinical Trials:
Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030
Global exosome market to grow at ~20% CAGR by 2030, driven by chronic disease incidence, diagnostic improvements, and personalized medicine interest. North America leads, with key players like Danaher and Thermo Fisher Scientific. Notable developments include Aruna Bio's US patent for neural exosomes and EXO Biologics' EUR 16 million Series A funding.
Resalis Therapeutics gets equity investment from Sanofi
Resalis Therapeutics secures strategic equity investment from Sanofi for its obesity therapy RES-10, targeting miR-22 to convert white fat cells into brown ones, reverse fibrosis, and restore lipid and energy homeostasis. The investment, expected to be €50m to €150m, will fund the programme up to Phase II. RES-010, the first locked nucleic acid targeting miR-22, shows potential in treating obesity, MAFLD, and MASH by modulating metabolic pathways. Unlike current GLP-1 modulators, RES-010 avoids muscle mass decrease and offers a more causal treatment for metabolic diseases. Resalis is preparing for a Phase I trial to assess RES-010's safety and therapeutic window.
How AZ's respiratory wins are ramping up for a bigger prize in COPD
Respiratory drug Fasenra, developed by AstraZeneca, has seen success in treating eosinophilic asthma and EGPA, with ongoing trials for COPD targeting patients with high eosinophil counts. Dr. Donna Carstens highlights the shift from 'treat-to-fail' to 'treat-to-target' in respiratory medicine, emphasizing the importance of precision and guideline-driven approaches.
Top 20 global biopharmaceutical companies witness 2% growth in market capitalization in Q3 2024
The biopharmaceutical industry saw a 2% upturn in aggregate market capitalization to $4.3 trillion in Q3 2024, driven by FDA approvals and interest rate cuts. Bristol-Myers Squibb, Gilead Sciences, Sanofi, AbbVie, and Alnylam Pharmaceuticals led with over 10% growth. Novo Nordisk and Merck faced declines due to FDA rejections and sales drops.
3 Black Medical Schools Receive Funding to Improve Clinical Trials
Sanofi invests $18 million over 10 years in Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine to establish Centers of Excellence for clinical study diversity, aiming to increase Black representation in clinical research and address historical disparities.
SWOT analysis: stock poised for growth amid FDA approvals
Syndax Pharmaceuticals, a biotech company focused on cancer therapies, is at a pivotal juncture with recent FDA approvals and upcoming product launches. Key developments include the approval of Niktimvo for cGVHD and the extended PDUFA date for revumenib in AML. The company's financial outlook is stable, with a strong cash position and a cash runway through 2026. Syndax's product pipeline, anchored by Niktimvo and revumenib, shows potential for expansion into new indications like CRC. Analysts maintain a positive outlook, with a consensus price target of $33.00, reflecting optimism about the company's growth trajectory.
Respiratory Syncytial Virus Pipeline 2024: Clinical Trials Assessment, FDA Approvals
DelveInsight's 'Respiratory Syncytial Virus Pipeline Insight, 2024' report details 50+ companies developing 50+ therapies, including Nirsevimab, Sisunatovir, and RSVpreF, across various stages of clinical trials. Key companies include GSK, Pfizer, and Sanofi, with recent successes like GSK's Arexvy vaccine and MSD's clesrovimab. The report covers mechanism of action, route of administration, and market dynamics.
© Copyright 2025. All Rights Reserved by MedPath